SynthesisMedicine2026
Prophylactic tirofiban versus oral dual antiplatelet therapy in patients undergoing endovascular treatment of intracranial aneurysms: A meta-analysis.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndovascular treatment of intracranial aneurysms carries the risk of perioperative thromboembolism and bleeding, and the optimal prophylactic antiplatelet strategy remains unclear. This study aimed to evaluate the efficacy and safety of prophylactic tirofiban administration compared with oral dual antiplatelet (DAP) therapy.
methodsWe searched PubMed, EMBASE, Cochrane Library, Web of Science, and Chinese National Knowledge Infrastructure databases for relevant studies up to August 2, 2023. All data analyses were conducted using RevMan 5.4 and Stata 14.0.
resultsEight randomized controlled trials with a total of 806 participants receiving endovascular treatment of intracranial aneurysms were included. The results indicated that prophylactic monotherapy with tirofiban was associated with significantly higher rate of good clinical outcome (risk ratio [RR]: 1.15, 95% confidence interval [CI]: 1.03-1.28, P = .01). It also reduced the incidence of thromboembolic (RR: 0.44, 95% CI: 0.26-0.74, P = .002) and hemorrhagic (RR: 0.47, 95% CI: 0.24-0.91, P = .03) events. Subgroup analyses further revealed the benefits of prophylactic tirofiban in combination with DAP therapy in reducing the incidence of hemorrhagic events, with a trend of reducing thromboembolic events. Meanwhile, prophylactic monotherapy with tirofiban reduced the incidence of thromboembolic events without increasing the incidence of hemorrhagic events. Sensitivity analyses demonstrated the robustness of all pooled results, but it was not possible to remove the negative impact of publication bias on the pooled results.
conclusionThese findings support the prophylactic administration of tirofiban to patients undergoing endovascular treatment of intracranial aneurysms, as it was associated with a significantly lower incidence of thromboembolic events without increasing the risk of hemorrhagic events. More studies are needed to determine differences between prophylactic monotherapy with tirofiban and prophylactic tirofiban in combination with DAP therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.